Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?

Ann Rheum Dis. 2014 Jun;73(6):951-3. doi: 10.1136/annrheumdis-2013-204934.
No abstract available

Keywords: DMARDs (biologic); Psoriatic Arthritis; Treatment.

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Psoriatic / drug therapy*
  • Arthritis, Psoriatic / immunology
  • Humans
  • Interleukin-12 / immunology
  • Interleukin-17 / immunology
  • Interleukin-23 / immunology
  • Isoxazoles / therapeutic use
  • Leflunomide
  • Methotrexate / therapeutic use
  • Signal Transduction / immunology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / immunology
  • Ustekinumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Interleukin-17
  • Interleukin-23
  • Isoxazoles
  • Tumor Necrosis Factor-alpha
  • Interleukin-12
  • secukinumab
  • Ustekinumab
  • Leflunomide
  • Methotrexate